Generic Semaglutide: Lower-Cost Semaglutide is Here!
BUY NOW
We Ship To The U.S. Only
Zepbound KwikPen® (Tirzepatide)
10% Off On Your First Order
Click on the Copy Code button to copy your code.
No Expiry
Exclusive On Duty Free Meds Only
Zepbound—along with many other GLP-1 receptor agonist medications for weight loss—has surged in popularity within the last year. The quick increase in popularity has led to widespread Zepbound stock shortages starting earlier in the year. It has been a hot topic, with many patients wondering when Zepbound will be back in stock and when it will be available to them. In this article, we will discuss the current state of the medication, estimated restocking timelines, and how to stay updated.
Zepbound KwikPen® (Tirzepatide)
10% Off On Your First Order
Click on the Copy Code button to copy your code.
No Expiry
Exclusive On Duty Free Meds Only
Weight loss medications have continued to grow in popularity this year. It was big news to many patients when medicine company Eli Lilly and Company announced they would be releasing single-dose vials of Zepbound in late August. This medication was promised at a rate of over 50% less compared to other similar obesity incretin medications. This medication was intended to provide a more affordable and accessible option to users.
The U.S. FDA announced earlier this year that the shortage of tirzepatide—the medication in Mounjaro and Zepbound—has officially ended. This change put a possible end to the use of less expensive compound variations that were permitted to be sold at lower prices during the shortage. These medications were temporarily allowed the company was working on making medications like Zepbound more accessible to the public again.
Availability has started to come back. Although Zepbound is now available to order from Canada, not all pharmacies have consistent availability. This is especially the case for the pen versions of the medication. Patients might still face occasional local shortages as the products move through the supply chain from manufacturers and distributors to local pharmacies.
The resupply of Zepbound is no simple task. Eli Lilly has to enhance production capacity and respond to rising demand. They also face distribution challenges and regulatory issues. The company is currently investing in manufacturing improvements and looking for innovative ways to distribute the drug.
Zepbound gained a lot of attention after it got official approval in November 2023. It was launched as a competitor of Novo Nordisk’s well-known weight loss drug, “Wegovy.” Some patients believed that this medication was even more impactful on their weight loss. The company behind Zepbound—Eli Lilly—is also the same company behind Monjaro. Mounjaro is another weight loss drug specifically for individuals with type 2 diabetes. Unlike Monjaro, Zepbound is available for anyone needing to lose extreme weight and facing weight related health conditions. It also proved to have incredible results in clinical trials. Eli Lilly added that patients would find it simpler to get ahold of this medication. It promised better coverage from commercial insurers, thus getting consumers excited and led to a fast-growing demand.
Zepbound was a huge success. However, the demand for the medication had quickly outpaced Eli Lilly’s capacity for making the medicine. Supplies were already unable to keep up with Zepbound demand just six months after the drug’s first release. Eli Lilly had to gradually investment of billions of dollars into its strategy of buying and expanding factories. Shortages may also continue to vary based on dose levels and other case-specific factors.
Eli Lilly launched new, cheaper versions of Zepbound at the end of August to tackle supply issues and make it easier for people to access the medication. They now offer single-dose vials for the 2.5 mg dose and the 5 mg dose. This increased demand for patients who did not have coverage or had to pay for the medication out of pocket.
There are a few different ways people get notified about Zepbound supplies as they come back in stock. For many people, it is signing up for a stock alert on official sites. This can be through the Lilly supply website directly or other official supply websites that will email the patient the moment it is available to them again. Some of these websites can also provide notifications from retailers, which are even easier to use, such as SMS or app notifications.
Third-party restock trackers, other than supplier websites, that can help patients include the Ro GLP-1 Supply Tracker and Together by Renee’s “Find My Meds” feature. On top of that, certain patients may also be able to stay updated by following official brand accounts and popular retail sites on social media.
Those for whom it is difficult to obtain Zepbound may consider other medication options. Similar medications to consider might include other brand-name medications, such as Mounjaro, Ozempic, and Wegovy. Not all these medications are built the same. Mounjaro and Ozempic can affect weight loss in patients, but their purpose is strictly for type 2 diabetes patients. Zepbound differs from Wegovy because it is a dual GIP/GLP-1 receptor agonists. Zepbound also provided a greater increase in loss of weight.
Another possible alternative is Saxenda and other alternatives include Qsymia, Contrave, and Alli. These are oral medications that need to be taken every day instead of once-weekly injections. The results of these medications have not shown the same level of effectiveness as Zepbound. All of these reasons are why Zepbound remains a leading option among other weight loss medications available on the market.
The ongoing Zepbound shortage and restocking problem has persisted for the past several months. Many are hopeful as the situation has appeared to already be resolving in some areas. Certain areas, however, are still experiencing low supply. Patients that want to know when their medication will be back in stock should remain patient, stay updated, and utilize notification services. Share your thoughts, questions, or any useful tips in the comments below, and let us know what solutions have worked for you!
Visit Duty Free Meds and order affordable weight loss medication online from a Canadian Pharmacy Partner.
First, call your doctor and inform them that your medication is out of stock at your specified pharmacy. Identify alternative pharmacies—online or brick-and-mortar—and contact them directly to ensure your medication is delivered before you miss a dose.
The answer depends on several factors, including your location. In 2023, the FDA announced a nationwide Zepbound shortage was resolved on October 3, 2024. Stock varies daily, so patients should give themselves a wide enough order and delivery window to avoid missing doses.
Generally speaking, Wegovy is less expensive than Zepbound. A patient’s final out-of-pocket cost is determined by several factors, including insurance coverage, dosage, and the prescribed supply. Medication-specific coupons and referral bonuses from Duty Free Meds can also help offset costs.
Zepbound can cost around $1,000 for a one-month supply.
As of October 3, 2024, the Zepbound shortage is considered resolved.
No, Zepbound is not out of stock everywhere. In October 2024, the FDA nationwide deemed the Zepbound shortage officially resolved. That said, it can still be hard to get in certain cases, and Zepbound inventory depends on where in the country you are located. This is what makes online pharmacies more convenient and cost-efficient.
Table of Contents
ToggleDisclaimer: The information presented here is intended solely for educational purposes and should not be interpreted as medical advice, a diagnosis, or specific treatment recommendations. It does not imply endorsement of any particular medication or therapy. Health conditions and treatment responses can differ significantly between individuals; thus, this information is not a guarantee of safety, suitability, or effectiveness for anyone in particular. Always seek the guidance of a healthcare professional for personalized medical advice and consult them before making any health or treatment decisions.